TX-EXPONENTIAL-TECH
15.12.2022 18:44:35 CET | Business Wire | Press release
Exponential Technology Group (XTG) today announced it has reached a definitive agreement to acquire Braemac Pty Ltd., a specialist in product design, development, testing, and the supply of semiconductors, systems, and electronic components. The financial terms of the deal were not disclosed.
Braemac is based in Sydney, Australia, with 17 offices globally and offers support from design through to product realization, driving innovation with industry-leading semiconductor and electronic component partners providing extensive design and supply chain management expertise.
“We welcome the Braemac team to the XTG family of companies,” said Glenn Smith, acting President of the Exponential Technology Group. “Braemac brings a very experienced management team and a business model that fits extremely well into XTG’s vision of helping engineers solve technical problems as well as having the experience and expertise to design a customer’s smart product from scratch, and then managing the bill-of-materials and supply chain through production.”
Behind these companies lies even more – the strength of XTG’s parent company, Mouser Electronics, a global authorized distributor of semiconductors and electronics components, recognized as the world leader in the introduction of new products with the widest selection of in-stock products for new designs. As a wholly-owned subsidiary of TTI Inc., Mouser and XTG are part of the Berkshire Hathaway family of companies.
According to Braemac President Jonathan Mitchell, “The Exponential Technology Group is a great fit for Braemac. Companies within XTG maintain their own areas of expertise and focus while collaborating within the group to deliver new technological solutions globally.”
Braemac was advised by Allier Capital and Norton Rose Fulbright Australia. XTG advisors in Australia were the law firm of Clayton Utz and PwC.
About Exponential Technology Group
Exponential Technology Group (XTG) is a collection of companies specializing in designing products and supplying semiconductors and electronic components that enable smart electronic systems in automotive, medical, wireless, industrial, and IoT. XTG operates as an independent member of the Mouser and TTI family of companies. The companies within the XTG group include the Design Services Companies of BGM Electronic Services, Connected Development, and Paragon Innovations, plus the supply chain experts and specialty semiconductor distributors of RFMW Ltd, Symmetry Electronics, Changnam I.N.T. LTD. To learn more, visit http://www.xponentialgroup.com/
About Braemac
Braemac is a leading distributor Headquartered in Australia, with 17 offices worldwide. Braemac supplies semiconductors, electronic components, interface products, systems, and services related to the end-product design, manufacture, and technical support for products, including single-board computers, displays, power supplies, cable assemblies, as well as value-added product assembly, and turnkey products. To learn more, visit http://www.braemac.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221215005852/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release
The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t
Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom